Found: 285
Select item for more details and to access through your institution.
Optimising classification of Parkinson's disease based on motor, olfactory, neuropsychiatric and sleep features.
- Published in:
- NPJ Parkinson's Disease, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41531-021-00226-2
- By:
- Publication type:
- Article
Improving estimation of Parkinson's disease risk—the enhanced PREDICT-PD algorithm.
- Published in:
- NPJ Parkinson's Disease, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41531-021-00176-9
- By:
- Publication type:
- Article
Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis.
- Published in:
- Digital Health, 2023, p. 1, doi. 10.1177/20552076231173531
- By:
- Publication type:
- Article
Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis.
- Published in:
- Digital Health, 2023, v. 9, p. 1, doi. 10.1177/20552076231173531
- By:
- Publication type:
- Article
The BRadykinesia Akinesia INcoordination (BRAIN) Tap Test: Capturing the Sequence Effect.
- Published in:
- Movement Disorders Clinical Practice, 2019, v. 6, n. 6, p. 462, doi. 10.1002/mdc3.12798
- By:
- Publication type:
- Article
The Rebif® New Formulation Story: It’s Not Trials and Error.
- Published in:
- Drugs in R&D, 2007, v. 8, n. 6, p. 335, doi. 10.2165/00126839-200708060-00002
- By:
- Publication type:
- Article
Neuroprotection in an Experimental Model of Multiple Sclerosis via Opening of Big Conductance, Calcium-Activated Potassium Channels.
- Published in:
- Pharmaceuticals (14248247), 2023, v. 16, n. 7, p. 972, doi. 10.3390/ph16070972
- By:
- Publication type:
- Article
Impact of multiple sclerosis risk alleles on the plasma proteome.
- Published in:
- Brain: A Journal of Neurology, 2024, v. 147, n. 2, p. e17, doi. 10.1093/brain/awad363
- By:
- Publication type:
- Article
Survival: the ultimate long-term outcome in multiple sclerosis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Peripheral blood neurofilament light chain levels: the neurologist's C-reactive protein?
- Published in:
- 2018
- By:
- Publication type:
- journal article
Comparison of two commercial ELISA systems for evaluating anti-EBNA1 IgG titers.
- Published in:
- Journal of Medical Virology, 2013, v. 85, n. 1, p. 128, doi. 10.1002/jmv.23446
- By:
- Publication type:
- Article
Increased expression of colony‐stimulating factor‐1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss.
- Published in:
- Glia, 2018, v. 66, n. 10, p. 2108, doi. 10.1002/glia.23464
- By:
- Publication type:
- Article
Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2021, p. 1, doi. 10.1177/20552173211024298
- By:
- Publication type:
- Article
Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2021, v. 7, n. 3, p. 1, doi. 10.1177/20552173211024298
- By:
- Publication type:
- Article
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-la.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2018, v. 4, n. 2, p. 1, doi. 10.1177/2055217318760642
- By:
- Publication type:
- Article
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2018, v. 4, n. 2, p. 1, doi. 10.1177/2055217318783767
- By:
- Publication type:
- Article
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2018, v. 4, n. 1, p. 1, doi. 10.1177/2055217318760642
- By:
- Publication type:
- Article
Multiple sclerosis cerebrospinal fluid biomarkers.
- Published in:
- Disease Markers, 2006, v. 22, n. 4, p. 187, doi. 10.1155/2006/509476
- By:
- Publication type:
- Article
Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-34384-5
- By:
- Publication type:
- Article
No evidence for an association between alcohol consumption and Multiple Sclerosis risk: a UK Biobank study.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-26409-2
- By:
- Publication type:
- Article
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.763433
- By:
- Publication type:
- Article
Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis.
- Published in:
- Multiple Sclerosis (13524585), 2007, v. 13, n. 5, p. 567, doi. 10.1177/1352458506073522
- By:
- Publication type:
- Article
MS care: integrating advanced therapies and holistic management.
- Published in:
- Frontiers in Neurology, 2024, p. 1, doi. 10.3389/fneur.2023.1286122
- By:
- Publication type:
- Article
Vitamin D deficiency - do we follow our own advice?
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Vitamin D deficiency - do we follow our own advice?
- Published in:
- Clinical Medicine, 2011, v. 11, n. 6, p. 521, doi. 10.7861/clinmedicine.11-6-521
- By:
- Publication type:
- Article
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2024, p. 1, doi. 10.1177/17562864241277736
- By:
- Publication type:
- Article
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2023, p. 1, doi. 10.1177/17562864231200627
- By:
- Publication type:
- Article
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2023, p. 1, doi. 10.1177/17562864231194823
- By:
- Publication type:
- Article
Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2023, p. 1, doi. 10.1177/17562864231180734
- By:
- Publication type:
- Article
Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2023, v. 16, p. 1, doi. 10.1177/17562864231180734
- By:
- Publication type:
- Article
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2023, v. 16, p. 1, doi. 10.1177/17562864231194823
- By:
- Publication type:
- Article
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2023, v. 16, p. 1, doi. 10.1177/17562864231200627
- By:
- Publication type:
- Article
Smouldering multiple sclerosis: the 'real MS'.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2022, p. 1, doi. 10.1177/17562864211066751
- By:
- Publication type:
- Article
Smouldering multiple sclerosis: the ‘real MS’.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2022, v. 15, p. 1, doi. 10.1177/17562864211066751
- By:
- Publication type:
- Article
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2021, p. 1, doi. 10.1177/17562864211058298
- By:
- Publication type:
- Article
Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB<sub>1</sub> on neurons and CB<sub>2</sub> on autoreactive T cells.
- Published in:
- Nature Medicine, 2007, v. 13, n. 4, p. 492, doi. 10.1038/nm1561
- By:
- Publication type:
- Article
P2-155: Development of sensitive and specific ELISAs for three-repeat and four-repeat tau isoforms
- Published in:
- 2006
- By:
- Publication type:
- Abstract
P2-155: Development of sensitive and specific ELISAs for three-repeat and four-repeat tau isoforms
- Published in:
- 2006
- By:
- Publication type:
- Abstract
Social capital: Implications for neurology.
- Published in:
- Brain & Behavior, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1002/brb3.1169
- By:
- Publication type:
- Article
Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 14, p. 2263, doi. 10.1177/13524585221114997
- By:
- Publication type:
- Article
Extended dosing of monoclonal antibodies in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 13, p. 2001, doi. 10.1177/13524585211065711
- By:
- Publication type:
- Article
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1591, doi. 10.1177/13524585221083194
- By:
- Publication type:
- Article
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1526, doi. 10.1177/13524585221076717
- By:
- Publication type:
- Article
Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 8, p. 1219, doi. 10.1177/13524585211049392
- By:
- Publication type:
- Article
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 5, p. 842, doi. 10.1177/13524585211061335
- By:
- Publication type:
- Article
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 111, doi. 10.1177/13524585211010294
- By:
- Publication type:
- Article
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 10, p. 1564, doi. 10.1177/1352458520971819
- By:
- Publication type:
- Article
Regarding: Nicotinic acetylcholine receptors α7 and α9 modify tobacco smoke risk for multiple sclerosis.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIG MS study.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 6, p. 922, doi. 10.1177/1352458520936934
- By:
- Publication type:
- Article